Oncology / Posted 2 years ago

A study looking at blood and tissue samples to learn more about advanced cancer (PEACE)

The purpose of the PEACE study is to increase our understanding of the changes that occur in each patient’s cancer by looking at tumour samples taken from patients who have recently died. Our research group is particularly interested in ‘intratumour heterogeneity’, which tells us that in different parts of the same tumour there can be different gene abnormalities that can interact and dictate how a tumour behaves and therefore how a cancer can progress.
This study aims to (1) understand how cancers grow and spread, (2) identify gene abnormalities in different types of cancer, (3) identify markers within tumours that can predict whether a patient will respond to a particular anti-cancer therapy, (4) determine whether a single tissue sample is representative of the entire tumour, or whether multiple samples are required, (5) study the reasons for resistance to drug therapy, including the extent of intratumour heterogeneity and how this might influence a patient’s survival and response to treatment and (6) determine genetic abnormalities that allow the spread of cancer tumours by comparing tissue samples from primary and secondary tumours in the same patient.
The results of such a study could improve the treatment for future patients with advanced secondary cancer by identifying gene abnormalities, which we can target to treat the cancer, and by telling us how different cancers can progress and how we can try to prevent this.

  • Inclusion Criteria :
    • Any type of cancer (a solid tumour ) except leukaemia, lymphoma or myeloma and this cancer that has spread elsewhere in the body (advanced cancer )
    • A brain tumour
  • Exclusion Criteria :
    • Have, or have had, a serious infection such as hepatitis C, tuberculosis or Creutzfeldt-Jacob disease
    • Are HIV positive
    • Have a history of intravenous drug abuse in the last 5 years
    • Have any other medical condition or mental health problem that would prevent you from consenting to take part
  • Study start date : 01/01/2014
  • Study end date : 31/10/2021
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Professor Charles Swanton

No post found